Clinical trials: Pharynx Carcinoma
Nasopharyngeal Carcinoma
Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma
The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT01612286
- Testing
- endostatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Carcinoma, Squamous, Head and Neck Cancer
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
Background: Bortezomib acts on molecules in head and neck cancer cells that are important for the cells growth and survival. The drug may help make the cancer more sensitive to radiation and other chemotherapy drugs.
- Conditions
- Carcinoma, Squamous, Head and Neck Cancer, Oral Cancer, Laryngeal Cancer
- Trial name
- NCT01445405
- Testing
- Bortezomib (Velcade, PS-341), Cetuximab, Cisplatin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
TOMO Versus IMRT in Nasopharyngeal Carcinoma Patients
Tomotherapy is a new radiation planning and delivery technology which may allow for delivery of higher radiation doses with less damage to normal tissues.
- Trial name
- NCT03588403
- Testing
- TOMO, IMRT
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma (NPC)
Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma
The goal of this study is to investigate the outcomes of patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) or recurrent-metastatic nasopharyngeal carcinoma (RM-NPC) treated with a combination of immune…
- Trial name
- NCT06676293
- Testing
- Anti-PD1, asparaginase
- Where
- Taiwan
- Volunteers
- 8 people
- Sponsor
- Chang Gung Memorial Hospital
Nasopharyngeal Carcinoma
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
In order to explore the efficacy and safety of targeted therapy and immunotherapy combined with GP chemotherapy in the treatment of high risk advanced nasopharyngeal carcinoma, the investigators design a single-arm, Phase II…
- Trial name
- NCT06851247
- Testing
- Toripalimab, Anlotinib, Gemcitabine
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Oropharynx Cancer, HPV-Related Carcinoma
Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
This study seeks to study the population of HPV-related oropharynx cancer patients that appear to be at highest risk for treatment failure with loco-regional failure and distant metastases including cT4 or cN3.
- Trial name
- ARTHOUSE (NCT06234748)
- Testing
- Radiation, Platinum based chemotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Michigan Rogel Cancer Center
Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by…
- Conditions
- Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx
- Trial name
- NCT03093909
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Oropharynx Cancer
Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma
The Phase III study will include 174 patients with locally advanced oropharynx carcinoma, receiving all arc-IMRT (Intensity-Modulated Radiation Therapy) (70 Gy) with concomitant systemic therapy.
- Trial name
- ARTIX (NCT01874587)
- Testing
- adaptative radiotherapy
- Where
- 11 sites in France
- Volunteers
- 132 people
- Sponsor
- Center Eugene Marquis
Nasopharyngeal Neoplasms, Mortality
Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.
This study evaluates the hyperfractionated IMRT in the treatment of patients with locally recurrent nasopharyngeal carcinoma. Half of participants will receive hyperfractionated IMRT, while the other half will receive…
- Conditions
- Nasopharyngeal Neoplasms, Mortality, Quality of Life, Complications
- Trial name
- NCT02456506
- Testing
- Hyperfractionated IMRT, Conventional Fraction IMRT
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Sun Yat-sen University
Head and Neck Neoplasms
Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection
Treatment of regionally-advanced head and neck squamous cell carcinoma (HNSCC) requires a multidisciplinary approach with a combination of surgery, radiotherapy (RT) and chemotherapy.
- Trial name
- UPFRONT-NECK (NCT02918955)
- Testing
- up-front neck dissection, radiotherapy, Chemotherapy (Cisplatin)
- Where
- 2 sites in Switzerland
- Volunteers
- 65 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Nasopharyngeal Cancer
Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is carried out to find out the safety and recommended dose of CD137L-DC-EBV-VAX in nasopharyngeal cancer. CD137L-DC-EBV-VAX is a product made from one of our own immune system cells (dendritic cell, DC).
- Trial name
- NCT03282617
- Testing
- CD137L-DC-EBV-VAX
- Where
- Singapore
- Volunteers
- 55 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma
Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma
Through open-label, single-center, randomised clinical trials, we intend to demonstrate that PD-1 treatment added to salvage surgery could further decrease the rate of disease progression and improve the survival outcome of…
- Trial name
- NCT05092217
- Testing
- Tirelizumab, salvage surgery
- Volunteers
- 80 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Nasopharyngeal Cancer, EBV Infections
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
To determine the safety of the combination of CD45 monoclonal antibody (Mab) followed by intravenous injection of EBV specific CTL in patients with nasopharyngeal cancer.
- Trial name
- CLANC (NCT00078546)
- Testing
- EBV specific CTL Infusion, Anti CD45 monoclonal antibody
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Baylor College of Medicine
Nasopharyngeal Carcinoma
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
The purpose of this study is to compare concurrent chemoradiotherapy (CCRT) alone with induction chemotherapy (gemcitabine+cisplatin) plus CCRT in patients with low-risk locoregionally advanced nasopharyngeal carcinoma(NPC).
- Trial name
- NCT05979961
- Testing
- IMRT and concurrent cisplatin, gemcitabine and cisplatin (Induction chemotherapy)
- Where
- 8 sites in China
- Volunteers
- 464 people
- Sponsor
- Sun Yat-sen University
HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Combination immune checkpoint inhibitor and DNA vaccine will result in clearance of HPV DNA biomarkers (oral and/or plasma) for patients with persistent HPV-16 E6/E7 DNA (HPV biomarker) after treatment with curative intent.
- Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma
- Trial name
- NCT04001413
- Testing
- MEDI0457, Durvalumab
- Where
- 4 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nasopharyngeal Carcinoma (NPC)
Prognostic Value of TIL in Nasopharyngeal Carcinoma
Our center plans to conduct a prospective, multicenter, observational study aimed at observing the percentage of TIL infiltration calculated using deep learning methods based on digital pathological images, and analyzing its…
- Trial name
- NCT06763640
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Nasopharyngeal Carcinoma
Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma
The primary objective of this study is to determine the tolerance and overall survival in patients with stage ⅣAB NPC treated with neoadjuvant chemotherapy and concurrent chemoradiation.
- Trial name
- NCT00816816
- Testing
- docetaxel, cisplatin, fluorouracil
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Fudan University
Squamous Cell Carcinoma, Oropharynx Cancer
PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
This proposal explores the novel hypothesis that the variability in outcomes within the Intermediate Risk(IR) HPV-positive Oropharynx Squamous Cell Carcinoma(OPSCC) cohort can be exploited to identify a subpopulation that…
- Trial name
- NCT03342378
- Testing
- Intensity modulated radiotherapy (IMRT), PET-MRI
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Wisconsin, Madison
Nasopharyngeal Carcinoma
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
EGFR and COX-2 are involved in tumorigenesis, angiogenesis and metastases and are frequently over expressed in NPC.COX-2 and EGFR inhibitors are active in NPC.There is synergistic action between COX-2 and EGFR inhibitors.
- Trial name
- NCT00212108
- Testing
- celecoxib, gefitinib
- Where
- Singapore
- Volunteers
- 22 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
This trial is aimed to investigate whether additional adjuvant PD-1 antibody treatment could improve survival in high-risk nasopharyngeal carcinoma compared to metronomic capecitabine alone.
- Trial name
- NCT05342792
- Testing
- PD-1 antibody, Capecitabine
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.